Table 4.
Presence of leiomodin-1 antibodies in serum from persons with OAE and persons without epilepsy from Ituri Province, DRC.
| Parameter | Persons with OAE (N = 54) * |
Controls without Epilepsy (N = 61) |
p-Value |
|---|---|---|---|
| Age (median, IQR) | 19 (14–23) | 31 (15.5–46.5) | <0.001 |
| Male (N, %) | 30 (55%) | 49 (80%) | 0.004 |
| Nodding seizures (N, %) | 16 | NA | NA |
| Age of seizure onset (median, IQR) | 10 (7–13) | NA | NA |
| Ever treated with ivermectin (N, %) | 4 (7%) | 11 (19%) | 0.091 |
| Leiomodin-1 antibodies by CBA (N, %) | 6/52 (11%) | 14 (23%) | 0.113 |
| Leiomodin-1 antibodies by WB (N, %) | 23/54 (43%) | 30 (49%) | 0.479 |
| Leiomodin-1 antibodies positive, CBA and WB (N, %) | 5/52 (10%) | 12 (20%) | 0.136 |
| Leiomodin-1 antibodies positive, CBA or WB (N, %) | 24/54 (44%) | 32 (52%) | 0.391 |
IQR: interquartile range; NA: not applicable; CBA: cell-based assay; * CBA not conducted in two persons; WB: Western blot.